Effect of withdrawal from long-term use of temazepam, zopiclone or zolpidem as hypnotic agents on cognition in older adults
- 1.3k Downloads
The aim of this study was to assess the effect of withdrawal from the long-term use of temazepam, zopiclone or zolpidem as hypnotics drugs (here referred to as BZD) on cognitive performance.
Ninety-two adults (age ≥55 years) with primary insomnia and who were long-term daily users of BZD volunteered to participate in a 1-month medically supported withdrawal attempt from BZD use, with a subsequent 5-month follow-up. Withdrawal was based on plasma BZD measurements at baseline, at 1 month and during subsequent regular clinical appointments. Attention and psychomotor performance were measured using the CogniSpeed® at baseline and at 1, 2 and 6 months. Reaction times were determined in the Simple Reaction Time (SRT), Two-Choice Reaction Time (2-CRT) and Vigilance tests, and errors were measured by the 2-CRT and Vigilance tests. The cognition data of the withdrawal group were also compared with a cohort of BZD non-users.
Eighty-nine (97 %) participants (59 women, 30 men) were followed-up for a maximum of 6 months. During the follow-up period, changes in reaction times and errors did not differ between short-term withdrawers (no residual BZD at 1 month; N = 69), non-withdrawers (residual BZD at 1 month; N = 20) or long-term withdrawers (N = 34). Compared to the reaction times of the BZD-free cohort, those of BZD users were slower at baseline. The reaction times of BZD withdrawers based on the results of the SRT or 2-CRT tests during follow-up did not reach those of the BZD-free cohort, but there was no difference between these groups in the Vigilance test.
Long-term use of BDZ as hypnotic drugs by older adults is related to prolonged impairment of attentional and psychomotor cognitive functioning that persists for at least 6 months after withdrawal.
KeywordsTemazepam Zopiclone Zolpidem Withdrawal Cognition Long-term effects
Acknowledgments, author contributions and competing financial interests
See ESM Acknowledgments.
- 8.Billioti de Gage S, Bégaud B, Bazin F, Vermeeren A, Dartigues JF, Pèrés K, Kurth T, Pariente A (2012) Benzodiazepine use and risk of dementia: prospective population based study. BMJ 345:e6231. doi: 10.1136/bmj.e6231
- 11.Puustinen J, Nurminen J, Vahlberg T, Lyles A, Isoaho R, Raiha I, Kivelä SL (2012) CNS Medications as predictors of precipitous cognitive decline in the cognitively disabled aged: a longitudinal population-based study. Dement Geriatr Cogn Disord Extra 2:57–68. doi: 10.1159/000336710 CrossRefGoogle Scholar
- 20.Lähteenmäki R, Puustinen J, Vahlberg T, Lyles A, Neuvonen PJ, Partinen M, Räihä I, Kivelä S-L (2013) Melatonin for sedative withdrawal in older patients with primary insomnia: a randomised double-blind placebo-controlled trial. Br J Clin Pharmacol. doi: 10.1111/bcp.12294
- 23.Karakorpi M, Alhola P, Urrila AS, Kylmala M, Portin R, Kalleinen N, Polo-Kantola P (2006) Hormone treatment gives no benefit against cognitive changes caused by acute sleep deprivation in postmenopausal women. Neuropsychopharmacology 31(9):2079–2088. doi: 10.1038/sj.npp.1301056 PubMedCrossRefGoogle Scholar
- 24.American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington, DCGoogle Scholar
- 25.Otmani S, Demazieres A, Staner C, Jacob N, Nir T, Zisapel N, Staner L (2008) Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers. Hum Psychopharmacol 23(8):693–705. doi: 10.1002/hup.980 PubMedCrossRefGoogle Scholar
- 35.Portin R, Revonsuo A, Koivikko L, Rinne J (1992) Kognitiivinen hitaus ja vanheneminen [Cognitive slowness and ageing]. Gerontologia [Gerontology] 6(3):196–210Google Scholar